Nationwide Fund Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Nationwide Fund Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-716	Closed	-$453K	–	3302
2015 Q2	$453K	Buy	716 +535	+296%	+$284K	﹤0.01%	2298
2015 Q1	$93K	Sell	181 -310	-63%	-$156K	﹤0.01%	2980
2014 Q4	$263K	Buy	491 +36	+8%	+$16.2K	﹤0.01%	2505
2014 Q3	$682K	Buy	455 +275	+153%	+$398K	﹤0.01%	2035
2014 Q2	$247K	Buy	180 +54	+43%	+$62.7K	﹤0.01%	2643
2014 Q1	$175K	Buy	126 +7	+6%	+$8.14K	﹤0.01%	2542
2013 Q4	$118K	Sell	119 -3	-2%	-$3.1K	﹤0.01%	2904
2013 Q3	$127K	Buy	122 +11	+10%	+$11.8K	﹤0.01%	2870
2013 Q2	$122K	Buy	+111	New	+$124K	﹤0.01%	2720

Other funds holding VIRX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nationwide Fund Advisors's VIRX Position: Q3 2015 in Review

Nationwide Fund Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 716 shares — an estimated $453K sold.

Nationwide Fund Advisors first reported a position in VIRX in Q2 2013 and held it in 9 quarters. The position peaked at $682K in Q3 2014. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

Nationwide Fund Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
Nationwide Fund Advisors sold 716 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $453K.
Nationwide Fund Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
Nationwide Fund Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $682K in Q3 2014.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Nationwide Fund Advisors's 13F filing for Q3 2015, filed 26 Oct 2015.